creutzfeldt-jakob

Migration, Crosslink

📖

creutzfeldt-jakob

active

wiki page Created: 2026-04-02T07:20:13 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-diseases-creutzfeldt-jakob

📖 Wiki Page

disease2402 wordssynced 2026-04-02

Creutzfeldt-Jakob Disease (CJD)

Introduction

creutzfeldt-jakob-disease (CJD) is a progressive neurodegenerative disorder characterized affecting millions worldwide. This page provides comprehensive information about the disease, including its mechanisms, symptoms, diagnosis, and treatment approaches. [@geschwind2015]

Overview

Creutzfeldt-Jakob Disease (CJD) is a rare, fatal, and rapidly progressive neurodegenerative disorder classified as a transmissible spongiform encephalopathy (TSE) or prion-disease. It is characterized by the accumulation of abnormal prion-protein (PrP^Sc) in the brain, leading to spongiform degeneration, neuronal loss, and astrocytic gliosis. CJD is the most common human Prion Disease, with an annual incidence of approximately 1-2 cases per million people worldwide (~350 cases annually in the United States) ([Geschwind, 2015](https://doi.org/10.1212/CON.0000000000000251)). [@prusiner1982]

The disease was first described independently by German neurologists Hans Gerhard Creutzfeldt in 1920 and Alfons Maria Jakob in 1921. [The connection to prions was not established until Stanley Prusiner's groundbreaking work in the 1980s, for which he received the Nobel Prize in Physiology or Medicine in 1997 ([Prusiner, 1982)](https://doi.org/10.1126/science.6801762)). The identification of variant CJD (vCJD) in 1996 provided the first evidence that bovine spongiform encephalopathy (BSE) could cross species barriers to infect humans ([Will et al., 1996](https://doi.org/10.1016/S0140-6736(96)91412-9)). [@will1996]

Types of Creutzfeldt-Jakob Disease

...

Creutzfeldt-Jakob Disease (CJD)

Introduction

creutzfeldt-jakob-disease (CJD) is a progressive neurodegenerative disorder characterized affecting millions worldwide. This page provides comprehensive information about the disease, including its mechanisms, symptoms, diagnosis, and treatment approaches. [@geschwind2015]

Overview

Creutzfeldt-Jakob Disease (CJD) is a rare, fatal, and rapidly progressive neurodegenerative disorder classified as a transmissible spongiform encephalopathy (TSE) or prion-disease. It is characterized by the accumulation of abnormal prion-protein (PrP^Sc) in the brain, leading to spongiform degeneration, neuronal loss, and astrocytic gliosis. CJD is the most common human Prion Disease, with an annual incidence of approximately 1-2 cases per million people worldwide (~350 cases annually in the United States) ([Geschwind, 2015](https://doi.org/10.1212/CON.0000000000000251)). [@prusiner1982]

The disease was first described independently by German neurologists Hans Gerhard Creutzfeldt in 1920 and Alfons Maria Jakob in 1921. [The connection to prions was not established until Stanley Prusiner's groundbreaking work in the 1980s, for which he received the Nobel Prize in Physiology or Medicine in 1997 ([Prusiner, 1982)](https://doi.org/10.1126/science.6801762)). The identification of variant CJD (vCJD) in 1996 provided the first evidence that bovine spongiform encephalopathy (BSE) could cross species barriers to infect humans ([Will et al., 1996](https://doi.org/10.1016/S0140-6736(96)91412-9)). [@will1996]

Types of Creutzfeldt-Jakob Disease

Sporadic CJD (sCJD)

Sporadic CJD accounts for approximately 85-90% of all cases and occurs spontaneously without known genetic or environmental-risk-factors ([Parchi et al., 1999](https://doi.org/10.1002/1531-8249(199912)46:6<731::AID-ANA2>3.0.CO;2-Y)): [@parchi1999]

Incidence: ~1-2 per million per year
Mean age of onset: 60-65 years
Median survival: 4-6 months (90% die within 1 year)
Cause: Unknown; possibly spontaneous misfolding of PrP^C or somatic PRNP mutations

sCJD is subtyped by the PRNP codon 129 genotype (MM, MV, or VV) and the PrP^Sc type (type 1 or type 2), creating six molecular subtypes with distinct clinical presentations: [@brown2000]

| Subtype | Frequency | Clinical Features | Duration | [@windl1999]
|---------|-----------|-------------------|----------| [@caughey2003]
| MM1/MV1 | ~70% | Classic: rapid dementia, myoclonus, EEG changes | 3-4 months | [@budka1995]
| VV2 | ~16% | Cerebellar ataxia, later dementia | 6-7 months | [@zerr2009]
| MV2 | ~9% | Ataxia, dementia, longer course | 17-18 months | [@mcguire2012]
| MM2-cortical | ~2% | Progressive dementia, longer course | 15-16 months | [@raymond2019]
| MM2-thalamic | ~2% | Insomnia, dysautonomia (sporadic fatal insomnia) | 16 months | [@mead2003]
| VV1 | ~1% | Early onset, progressive dementia | 15-21 months | [@bhatt2024]

Familial CJD (fCJD)

Familial CJD comprises about 10-15% of cases and follows autosomal dominant inheritance with PRNP gene mutations on chromosome 20p13 ([Windl et al., 1999](https://doi.org/10.1007/s004150050341)): [@collins2004]

E200K mutation: Most common worldwide; similar clinical presentation to sCJD but with younger onset
D178N with valine at codon 129: Produces familial CJD phenotype
D178N with methionine at codon 129: Produces fatal familial insomnia (FFI) phenotype
V210I, R208H, E196K: Other pathogenic mutations with varying penetrance

Over 50 pathogenic PRNP mutations have been identified. Genetic counseling is recommended for all families with inherited Prion Disease. [@prusiner1998]

Iatrogenic CJD (iCJD)

Iatrogenic CJD results from accidental transmission of prions through medical procedures ([Brown et al., 2000](https://doi.org/10.1212/WNL.55.8.1075)): [@national]

Dura mater grafts (Lyodura): Largest source; primarily reported from Japan
Pituitary-derived growth hormone: Over 200 cases worldwide before recombinant hormone became available
Corneal transplants: Rare cases documented
Contaminated neurosurgical instruments: Historical cases; standard autoclaving is insufficient for prion inactivation
Blood transfusion: Four confirmed cases of vCJD transmission in the UK

Variant CJD (vCJD)

Variant CJD was first identified in 1996 in the UK and is causally linked to bovine spongiform encephalopathy (BSE) ([Will et al., 1996](https://doi.org/10.1016/S0140-6736(96)91412-9)):

Median age of onset: 28 years (significantly younger than sCJD)
Duration: 12-14 months
Cumulative cases: ~230 worldwide (majority in UK)
Clinical features: Prominent early psychiatric symptoms (depression, anxiety, behavioral changes) and painful sensory symptoms preceding dementia and ataxia
Genetic susceptibility: All definite clinical cases to date have been methionine homozygous (MM) at codon 129

Pathophysiology

Prion Protein Conversion

The central event in CJD is the conformational conversion of normal PrP^C into PrP^Sc. This post-translational process transforms the alpha-helix-rich structure of PrP^C into a beta-sheet-dominated conformation that is insoluble, protease-resistant, and self-propagating ([Caughey & Lansbury, 2003](https://doi.org/10.1146/annurev.neurosci.26.010302.081142)).

Mechanisms of Neuronal Damage

Multiple interconnected pathways contribute to neurodegeneration:

endoplasmic-reticulum-stress (endoplasmic-reticulum-stress activation: PrP^Sc accumulation in the endoplasmic reticulum triggers chronic endoplasmic-reticulum-stress activation, leading to sustained translational repression via PERK-eIF2alpha signaling and eventual neuronal death

oxidative-stress: Increased oxidative-stress production, mitochondrial-dysfunction, and depleted antioxidant defenses

Synaptic dysfunction: Early and progressive synaptic loss affecting neurotransmission, particularly in the cortex, hippocampus, and cerebellum

**Microglial ([Budka et al., 1995](https://doi.org/10.1111/j.1750-3639.1995.tb00625.x))

Clinical Presentation

Core Clinical Triad

Rapidly progressive dementia: Global cognitive decline progressing over weeks to months, often beginning with memory difficulties and progressing to akinetic mutism

Myoclonus: Involuntary, stimulus-sensitive jerking movements; present in ~80% of sCJD

Cerebellar ataxia: Gait instability, incoordination, and dysmetria

Additional Neurological Features

Cortical blindness (Heidenhain variant): Visual disturbances as the presenting feature
Pyramidal signs: Spasticity, hyperreflexia, Babinski sign
Extrapyramidal signs: Parkinsonism, dystonia, choreoathetosis
Speech dysfunction: Dysarthria progressing to mutism
Seizures: Focal or generalized, in ~10-15% of cases

Psychiatric and Behavioral Symptoms

Depression, anxiety, apathy, agitation, and psychosis may occur, particularly early in vCJD. Initial psychiatric presentation is common in vCJD and younger patients, often delaying the correct diagnosis by weeks to months.

Diagnosis

Updated Diagnostic Criteria

The updated criteria ([Zerr et al., 2009](https://doi.org/10.1093/brain/awp191)) classify sCJD as:

Definite: Neuropathological confirmation with PrP^Sc detection by immunohistochemistry or Western blot
Probable: Progressive dementia + at least 2 of 4 clinical features (myoclonus, visual/cerebellar, pyramidal/extrapyramidal, akinetic mutism) + supportive investigation (EEG, MRI, or CSF)
Possible: Progressive dementia + clinical features but lacking supportive investigation findings

Diagnostic Investigations

MRI Brain (most useful imaging modality):

Diffusion-weighted imaging (DWI): Cortical ribboning and/or caudate/putamen hyperintensity; sensitivity ~92%, specificity ~95%
FLAIR: May show similar patterns but less sensitive than DWI
Cortical atrophy: Progressive with disease

Real-Time Quaking-Induced Conversion (RT-QuIC):

Ultrasensitive assay detecting PrP^Sc seeding activity in CSF
Sensitivity ~92%, specificity ~100% for sCJD
Can be performed on nasal brushings (sensitivity ~97%) and skin biopsies
Has transformed pre-mortem diagnosis ([McGuire et al., 2012](https://doi.org/10.1002/ana.23590))

CSF Biomarkers:

14-3-3 protein: Sensitivity ~85-95%, specificity ~75-85%; reflects rapid neuronal destruction
Total tau]: Markedly elevated (>1,150 pg/mL); correlates with disease progression
nfl-protein (NfL))): Elevated; reflects axonal damage
RT-QuIC: See above

EEG: Periodic sharp wave complexes (PSWC) in 60-80% of sCJD (mainly MM1/MV1 subtypes); typical 1-2 Hz generalized periodic discharges

PRNP Gene Sequencing: Essential for identifying familial forms; codon 129 genotyping provides subtype classification

Brain Biopsy/Autopsy: Gold standard; reserved for atypical cases. Immunohistochemistry for PrP^Sc provides definitive diagnosis.

Treatment

Current Management

There is no cure for CJD. All [treatments are supportive and palliative:

Myoclonus: Clonazepam (first-line), sodium valproate, levetiracetam
Seizures: Standard antiepileptic medications
Pain: Standard analgesic protocols; opioids for severe pain
Psychiatric symptoms: Cautious use of antipsychotics and anxiolytics
Dysphagia: Swallowing assessment; PEG tube consideration
Physical therapy: Maintain mobility and comfort
Palliative care: Early involvement of palliative care teams
Family support: Genetic counseling for familial cases; psychological support

Experimental Therapeutic Approaches

Antisense oligonucleotides (ASOs): Targeting PRNP mRNA to reduce PrP^C expression; the most promising therapeutic strategy based on preclinical data showing up to 98% survival extension in mice ([Raymond et al., 2019](https://doi.org/10.1172/jci.insight.131175))

immunotherapy: Anti-PrP antibodies and vaccination approaches; limited by blood-brain-barrier penetration

Small molecule inhibitors:

Efavirenz (anti-HIV drug): Extended survival in scrapie-infected mice via brain cholesterol regulation ([JCI Insight, 2024](https://doi.org/10.1172/jci.insight.190296))
Anle138b: Oligomer modulator with preclinical efficacy

4. Gene therapy: AAV-mediated delivery of anti-prion constructs and CRISPR-based PRNP silencing (preclinical)

Past [clinical trials of quinacrine, pentosan polysulfate, and doxycycline have not demonstrated clear efficacy.

Brain-Computer Interface Therapy

Brain-computer interfaces (BCIs) offer potential applications for monitoring and supportive care in Creutzfeldt-Jakob Disease, primarily for patients with advanced disease who lose motor and communication abilities[@wolpaw2004].

Current Applications

Cognitive monitoring: EEG-based BCI can track cortical function and detect changes in neural activity
Communication support: For patients in locked-in state or with severe motor impairment
Neurophysiological biomarkers: Neural signals may aid in disease monitoring
Palliative care integration: BCI for environmental control in hospice settings

Emerging Technologies

Rapid cognitive assessment: BCI-based tools for quick cognitive evaluation
Neural biomarker development: Using BCI signals for prion disease detection
Home monitoring systems: Non-invasive BCI for continuous patient monitoring

Clinical Evidence

BCI applications in CJD are primarily exploratory. The rapid progression of the disease limits therapeutic interventions, but BCI for communication in the terminal phase has been studied. EEG abnormalities in CJD are well-documented, providing a basis for neural monitoring approaches[@collins2000].

Cross-References

EEG Brain-Computer Interface
Brain-Computer Interface Technologies
Non-Invasive Home BCI Technology

[@wolpaw2004]: Wolpaw JR, et al. Brain-computer interfaces for communication and control. Proceedings of the IEEE. 2004;92(7):1082-1093. Available from: https://doi.org/10.1109/JPROC.2004.829006

[@collins2000]: Collins JD, et al. EEG findings in Creutzfeldt-Jakob disease. Clinical Neurophysiology. 2000;111(11):1960-1967. Available from: https://doi.org/10.1016/s1388-2457(00)00441-5

Differential Diagnosis

Conditions that may mimic CJD include:

alzheimers (rapidly progressive variant)
lewy-body-dementia (rapid cognitive decline with movement disorder)
ftd (behavioral variant)
Autoimmune encephalitis (anti-nmda-receptor receptor] receptor] receptor, anti-LGI1, anti-CASPR2)
Paraneoplastic neurological syndromes
CNS vasculitis
Viral encephalitis (HSV, EBV)
Hashimoto's encephalopathy (steroid-responsive encephalopathy)
Non-convulsive status epilepticus
Metabolic encephalopathies (hepatic, uremic)

Autoimmune encephalitis is an especially important differential diagnosis, as it is treatable and increasingly recognized.

Epidemiology

| Feature | sCJD | fCJD | iCJD | vCJD |
|---------|------|------|------|------|
| Frequency | 85-90% | 10-15% | <1% | <1% |
| Mean onset age | 60-65 yrs | 50-60 yrs | Variable | 28 yrs |
| Median survival | 4-6 months | Variable | Variable | 12-14 months |
| Sex ratio (M:F) | 1.2:1 | 1:1 | Variable | ~1:1 |
| Cause | Spontaneous | PRNP mutation | Medical exposure | BSE prions |

Genetics

The PRNP gene polymorphisms profoundly influence disease susceptibility and phenotype:

Codon 129 polymorphism: The most important genetic modifier. Homozygosity (MM or VV) increases risk for sCJD and vCJD. ~70% of sCJD patients are MM at codon 129 versus ~40% in the general European population.
Pathogenic mutations: Over 50 mutations identified (E200K, D178N, V210I, P102L, etc.)
Protective heterozygosity: MV heterozygosity at codon 129 appears protective against both sCJD and vCJD ([Mead et al., 2003](https://doi.org/10.1073/pnas.0937733100))

Prognosis

CJD is uniformly fatal:

sCJD: ~90% of patients die within 1 year of symptom onset; median survival 4-6 months
fCJD: Variable; some forms (E200K) similar to sCJD; others (P102L/GSS) may survive 2-10 years
vCJD: Median survival 12-14 months
Death typically results from pneumonia, other infections, or central respiratory failure in the terminal akinetic mutism stage

Background

The study of Creutzfeldt Jakob Disease (Cjd) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

[Diseases Index
[Prion Diseases
[Neurodegeneration
[Dementia

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
[Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
[Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Recent Research (2024-2026)

Recent advances in Creutzfeldt-Jakob Disease have focused on understanding disease mechanisms, identifying biomarkers, and developing novel therapeutic approaches. Key developments include:

Genetic studies: Identification of new genetic risk factors and mechanistic insights
Biomarker research: Development of diagnostic and prognostic biomarkers
Therapeutic approaches: Investigation of novel treatment strategies
Clinical trials: Ongoing Phase I-III trials for new therapies

Prion Disease Pathogenesis

Mermaid diagram (expand to render)

CJD Pathogenesis Overview

PrP<sup>Sc</sup> Formation: Abnormal prion protein undergoes conformational change

Seed-dependent Aggregation: Misfolded proteins act as seeds for further misfolding

Neurodegeneration: Spongiform degeneration leads to rapid cognitive decline

Clinical Progression: Typical disease duration is 4-6 months

References

[DOI:10.1212/CON.0000000000000251](https://doi.org/10.1212/CON.0000000000000251)

[Unknown, Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. 1982;216(4542):136-144. [DOI (1982)](https://doi.org/10.1126/science.6801762)

[Will RG, Ironside JW, Zeidler M, et al., A new variant of Creutzfeldt-Jakob Disease in the UK. Lancet. 1996;347(9006):921-925. [DOI (1996)](https://doi.org/10.1016/S0140-6736(96)

[Parchi P, Giese A, Capellari S, et al., Classification of sporadic Creutzfeldt-Jakob Disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol. 1999;46(6):731-741. [DOI (1999)](https://doi.org/10.1002/1531-8249(199912)

[Brown P, Preece M, Brandel JP, et al., Iatrogenic Creutzfeldt-Jakob Disease at the millennium. Neurology. 2000;55(8):1075-1081. [DOI (2000)](https://doi.org/10.1212/WNL.55.8.1075)

[Windl O, Giese A, Schulz-Schaeffer W, et al. Molecular, genetics of human prion diseases in Germany. Hum Genet. 1999;105(3):244-252. [DOI (1999)](https://doi.org/10.1007/s004150050341)

[Unknown, Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration. Annu Rev Neurosci. 2003;26:267-298. [DOI (2003)](https://doi.org/10.1146/annurev.neurosci.26.010302.081142)

[Budka H, Aguzzi A, Brown P, et al., Neuropathological diagnostic criteria for Creutzfeldt-Jakob Disease. Brain Pathol. 1995;5(4):459-466. [DOI (1995)](https://doi.org/10.1111/j.1750-3639.1995.tb00625.x)

[Zerr I, Kallenberg K, Summers DM, et al., Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob Disease. Brain. 2009;132(10):2659-2668. [DOI (2009)](https://doi.org/10.1093/brain/awp191)

[McGuire LI, Peden AH, Orru CD, et al., Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic Creutzfeldt-Jakob Disease. Ann Neurol. 2012;72(2):278-285. [DOI (2012)](https://doi.org/10.1002/ana.23590)

[Raymond GJ, Zhao HT, Race B, et al., Antisense oligonucleotides extend survival of prion-infected mice. JCI Insight. 2019;4(16):e131175. [DOI (2019)](https://doi.org/10.1172/jci.insight.131175)

[Mead S, Stumpf MP, Whitfield J, et al., Balancing selection at the prion protein gene consistent with prehistoric kuru-like epidemics. Science. 2003;300(5619):640-643. [DOI (2003)](https://doi.org/10.1073/pnas.0937733100)

[Bhatt D, et al., Treatment with efavirenz extends survival in a Creutzfeldt-Jakob Disease model. JCI Insight. 2024;9(22):e190296. [DOI (2024)](https://doi.org/10.1172/jci.insight.190296)

[Unknown, Collins SJ, Lawson VA, Masters CL. Transmissible spongiform encephalopathies. Lancet. 2004;363(9402):51-61. [DOI (2004)](https://doi.org/10.1016/S0140-6736(03)

[Unknown, Prusiner SB. Prions. Proc Natl Acad Sci USA. 1998;95(23):13363-13383. [DOI (1998)](https://doi.org/10.1073/pnas.95.23.13363)

Unknown, National Prion Disease Pathology Surveillance Center. [Case Western Reserve University] — Microglial activation in prion diseases (n.d.)

[Wolpaw JR, et al, Brain-computer interfaces for communication and control (2004)](https://doi.org/10.1109/JPROC.2004.829006)

[Collins JD, et al, EEG findings in Creutzfeldt-Jakob disease (2000)](https://doi.org/10.1016/s1388-2457(00)

📖 View canonical wiki page →

Related Entities

diseases-creutzfeldt-jakob

▸Metadataorigin_type: v1_polymorphic_backfill

slug	diseases-creutzfeldt-jakob
kg_node_id	None
entity_type	disease
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-85a769dc1cc5
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'diseases-creutzfeldt-jakob'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

23

Outgoing

5

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

creutzfeldt-jakob

Creutzfeldt-Jakob Disease (CJD)

Introduction

Overview

Types of Creutzfeldt-Jakob Disease

Creutzfeldt-Jakob Disease (CJD)

Introduction

Overview

Types of Creutzfeldt-Jakob Disease

Sporadic CJD (sCJD)

Familial CJD (fCJD)

Iatrogenic CJD (iCJD)

Variant CJD (vCJD)

Pathophysiology

Prion Protein Conversion

Mechanisms of Neuronal Damage

Clinical Presentation

Core Clinical Triad

Additional Neurological Features

Psychiatric and Behavioral Symptoms

Diagnosis

Updated Diagnostic Criteria

Diagnostic Investigations

Treatment

Current Management

Experimental Therapeutic Approaches

Brain-Computer Interface Therapy

Current Applications

Emerging Technologies

Clinical Evidence

Cross-References

Differential Diagnosis

Epidemiology

Genetics

Prognosis

Background

External Links

Recent Research (2024-2026)

Prion Disease Pathogenesis

CJD Pathogenesis Overview

References

💬 Discussion